Retinoblastoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Retinoblastoma Market Outlook

Thelansis’s “Retinoblastoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Retinoblastoma   treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Retinoblastoma Overview

Retinoblastoma, although rare, stands as the predominant ocular neoplasm in childhood. It emerges as a malignant proliferation originating from the developing retina, typically manifesting before age five. This tumor arises from cells harboring cancer-predisposing variants in both alleles of the RB1 gene. Its presentation may be unifocal or multifocal. Approximately 60% of cases present as unilateral retinoblastoma, with a mean diagnosis age of 24 months, while around 40% present with bilateral involvement, typically diagnosed at 15 months of age. Heritable retinoblastoma follows an autosomal dominant pattern, increasing susceptibility to the disease and predisposing affected individuals to non-ocular tumors. The prognosis of localized disease is favorable for long-term survival, in stark contrast to metastatic retinoblastoma, characterized by aggressive behavior and dismal outcomes. The genetic underpinning of retinoblastoma is well-established, with evidence suggesting autosomal dominant inheritance, particularly notable in bilateral cases. Retinoblastoma treatment strategies are comprehensive and aim at life-saving and vision-preserving measures. Intraocular disease exhibits high responsiveness to treatment, with over 90% of patients achieving survival. Chemotherapeutic regimens, such as the combination of carboplatin, etoposide phosphate, and vincristine sulfate, capitalize on synergistic effects to enhance efficacy, exploiting distinct mechanisms of action against cancer cells.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Retinoblastoma  – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034